- Home
- RBOT vs KPTI Comparison
RBOT vs KPTI Comparison
Compare RBOT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | KPTI |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 172.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | RBOT | KPTI |
|---|---|---|
| Price | $1.98 | $8.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.00 | ★ $22.17 |
| AVG Volume (30 Days) | 61.0K | ★ 771.0K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | $0.84 |
| Revenue Next Year | N/A | $46.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.71 | $3.51 |
| 52 Week High | $13.75 | $10.99 |
Technical Indicators
Market Signals| Indicator | RBOT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 52.34 |
| Support Level | $1.76 | $5.60 |
| Resistance Level | $2.41 | $8.95 |
| Average True Range (ATR) | 0.20 | 0.83 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 38.63 | 21.01 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).